Given the robust claims of Spruce's US Patent No. 11,344,557 and Neurocrine's stock chart performance, the patent's invalidation would likely be both challenging and detrimental to the plaintiff.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.